Prevision Medicine
Switzerland · Healthtech
Tests living patient cancer cells against drugs and combinations to help oncologists compare treatment options.
Testing the patient’s cells
Prevision Medicine develops PrevisionOne, a laboratory platform that measures how a patient’s living cancer cells respond to treatments. Samples from blood cancers or solid-tumour biopsies are tested against more than 100 drugs and combinations.
Automated microscopy and analysis track the responses of cancer and non-cancer cells. The resulting report ranks treatment options using the observed response, adding functional evidence to the information available to the treating oncologist.
A report for clinical decisions
The company says its workflow delivers a report within three days. It works with clinical teams that need patient-specific evidence when comparing potential treatments.
Funding history
2 rounds · 0 with disclosed amounts| Announced | Round | Amount | Investors |
|---|---|---|---|
| Future of Health Grant Level 3 support | Undisclosed | Future of Health Grant — Participant | |
| Future of Health Grant Level 2 support | Undisclosed | Future of Health Grant — Participant |